CD34 and myelodysplastic syndrome: In this regard, a group recently showed that MSC-MVs of myelodysplastic syndrome (MDS) patients have different cargo compared with MSC-EVs from healthy donors and could adjust CD34+ hematopoietic progenitor cells (HPCs) characteristics such as increasing cell viability and clonogenicity and changing of miRNA and gene expression pattern in the co-culture system.148 As well as, investigations on MSC-EVs of myeloproliferative neoplasm (MPN) patients, showed that their total miRNA content especially miRNA155 increased compared with healthy donors.